Abbreviations: T2D, type 2 diabetes; SGLT2i, sodium–glucose cotransporter 2 inhibitor; SGLT1/2, sodium–glucose cotransporter 1 and 2; DPP-4, dipeptidyl peptidase 4; NAFLD, non-alcoholic fatty liver disease; CV, cardiovascular; HbA1c, glycated hemoglobin; RCT, randomized controlled trial. This evidence concerns the gene SLC5A1 and metabolic dysfunction-associated steatotic liver disease.